KCNJ10 and depressive disorder: Collectively, the findings of aforementioned studies provide persuasive evidence that Kir4.1 channel blockers or expressional suppressors of Kir4.1 channels are attractive candidates as novel therapeutic agents for the treatment of depressive disorders (Figure 4).